Navigation Links
Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference
Date:5/21/2008

ith gluten or gluten placebo during a 14 day period. Four doses of the oral formulation of larazotide acetate, all less than 10 mg, were given prior to each gluten challenge. Study endpoints included intestinal permeability (IP), measured as lactulose-mannitol ratio (LAMA), as well as patient signs and symptoms and outcomes, measured by the Gastrointestinal Symptoms Rating Scale (GSRS; validated in several gastrointestinal diseases) and the Psychological General Well-Being Index (PGWBI).

Clinical Findings:

* In the primary study outcome, the prevention of increase in LAMA ratio

from Day 0 to Day 14, the treatment groups showed a dose dependent

protection from increase in intestinal permeability as measured by LAMA

ratio versus placebo, however the difference was not statistically

significant

* In the highest dose active treatment groups of 4 and 8 mg, the LAMA

ratio did not increase after gluten exposure when compared with placebo

* Post-hoc analysis of change in LAMA ratio from Day 7 to Day 21 showed

dose dependent prevention of increase in LAMA across the 4 and 8 mg

treatment groups

* Changes in PGWBI scores and anti-tTG titers were not significant over

the time course of this study

* An unexpected enrollment effect resulted in a fall in intestinal

permeability from Day 0 to Day 7 across all groups suggesting the need

for a run-in period

* Larazotide acetate conferred protection from gastrointestinal symptoms

as measured by the GSRS as well as from expected signs and symptoms of

gluten toxicity

* Follow-up studies of longer duration are currently ongoing

Safety:

* There was no difference in rate of adverse events between Placebo and

Active Drug Groups (46% vs. 55%)

* No Serious Adverse Events (SAEs) were reported

* Headache was the most common AE (reported by
'/>"/>

SOURCE Alba Therapeutics Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis
2. Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease
3. PacificGMP Completes GMP Product Fill for Trius Therapeutics
4. Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
5. Vicus Therapeutics Records Last Patient Visit of Phase 2, VT-122 Trial for the Treatment of Cachexia in Patients With Advanced Lung Cancer
6. Cara Therapeutics Initiates Phase 1 Clinical Trial of Novel Analgesic, CR845
7. PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy
8. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
9. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
10. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
11. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ...
(Date:1/14/2014)... InformEx, North America,s leading business partnering ... the 30 th edition of its annual conference at ... January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... and specialty chemical companies will take part in the conference, ...
(Date:1/14/2014)... 2014 Animal Emergency Critical Care, a LifeCentre partner practice, located ... is the first in Loudoun County ... Dr. Susan M. Barnes , Medical Director, is a well-seasoned ... Cole Taylor , are avid scuba divers. "As altitude skiers ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Hyperbaric Veterinary Medicine (hvm) Announces Animal Emergency Critical Care Installs A Small Animal Hyperbaric Chamber 2
... OncoSec Medical Incorporated (OTCBB: ONCS), which is ... solid tumor cancers, announced today clinical study results ... Future of Ablation Therapies conference in Las Vegas, ... titled, "OMS ElectroChemotherapy: Targeted Ablation of Solid Tumors ...
... Nonin Medical, Inc., the inventor of finger pulse ... announced the launch of the Onyx® Vantage 9590 professional ... 2011 Annual Congress in The Netherlands. The Onyx® Vantage ... the presence of low perfusion. The new device features ...
Cached Medicine Technology:Update: OncoSec Announces Positive Results From Head & Neck and Breast Cancer Trials 2Update: OncoSec Announces Positive Results From Head & Neck and Breast Cancer Trials 3Update: OncoSec Announces Positive Results From Head & Neck and Breast Cancer Trials 4Nonin Medical Launches Onyx® Vantage 9590 Professional Finger Pulse Oximeter at ERS Annual Congress 2
(Date:4/17/2014)... Scientists have identified the first genetic variant specifically ... sub-type accounting for around 10-15 per cent of ... study of the breast cancer sub-type, called invasive ... genetic causes of this particular kind of breast ... The research, published today (Thursday) in the journal ...
(Date:4/17/2014)... in PLOS Pathogens , children who live in ... mount an immune response to infection with malaria parasites ... high fever and illness and partially control the growth ... help researchers develop future interventions that prevent or mitigate ... year, approximately 200 million cases of malaria occur worldwide, ...
(Date:4/17/2014)... Colo. (April 17, 2014) Two recent papers ... researcher and colleagues may help scientists develop treatments ... Yellow fever, Japanese encephalitis and other disease-causing flaviviruses. ... biochemistry and molecular genetics at the School of ... Howard Hughes Medical Institute, and colleagues recently published ...
(Date:4/17/2014)... A Northwestern University synthetic biology team has created ... create programmable therapeutics that could travel the body ... disease. , Engineering cell-based, biological devices that monitor ... in clinical synthetic biology. However, no existing technology ... a patient,s physiological state and respond in a ...
(Date:4/17/2014)... that as many as 10 million older Americans suffer ... and isolation. , However, new research a project ... Americans for six years found that Internet use ... by more than 30 percent. , "That,s a very ... professor of telecommunication, information studies and media who led ...
Breaking Medicine News(10 mins):Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:CU researchers discover target for treating dengue fever 2Health News:Building 'smart' cell-based therapies 2Health News:Internet use can help ward off depression among elderly 2
... ... Awards Ceremony Reminded Everyone of the Importance of One Simple Thing: Good Posture. ... (PRWEB) March 11, ... poor posture of some presenters than on the Vera Wang dresses or breakout performances ...
... ... of $25 or more for all hand and body lotions as well as facial serums. ... Southfield, Mich. (PRWEB) March ... lotions with an emphasis on the key ingredient African Shea butter. The products are highly ...
... ... few weeks, thousands of college students across the U.S. will travel abroad ... abusive drinking. Kathleen Quartaro, a Choose Responsibility volunteer and mother of a ... drinking during her freshman year, urges parents and students to discuss the ...
... ... put an end to decades of unethical and disinterested leadership in Northern Manhattan by supporting ... ... 2010 -- After decades of serving the men and women of New York City through ...
... ... Houston and will soon be expanding nationwide. Local IT Companies connects businesses with up to ... , ... It seems most business owners are entrenched in their own day to day business building ...
... ... company that takes pride in providing accurate information on sexuality and toys for grown-ups, ... , ... March 11, 2010 -- Good Vibrations , the legendary San Francisco-based company that takes ...
Cached Medicine News:Health News:Slouching Stars at the Oscars: Could the PostureNOW Posture Brace Have Helped Miley? 2Health News:Free Shipping On Hand and Body Lotions Made with African Shea Butter 2Health News:Mother of Binge Drinking Victim Urges Students and Parents to Discuss Signs of Alcohol Poisoning, Emphasize Peer Responsibility Prior to Spring Break 2Health News:Rev. Michel Faulkner Seeks to Retire Charlie Rangel from New York's 15th Congressional Seat 2Health News:Rev. Michel Faulkner Seeks to Retire Charlie Rangel from New York's 15th Congressional Seat 3Health News:LocalITCompanies.com now Helping Chicago, Dallas and Houston Businesses Find Pre-Screened IT Companies 2Health News:LocalITCompanies.com now Helping Chicago, Dallas and Houston Businesses Find Pre-Screened IT Companies 3Health News:Good Vibrations' Pleasure-Ed Series Brings High Quality Erotic Education to the Classroom and the Bedroom 2
... Healthcare is known as ... analysis programs for every ... device. With advanced programs ... and ACI-TIPI, GE can ...
For use in vitreo-retinal procedures with a non contact system, and compatible with the Oculus BIOM system, this lens delivers the highest image clarity available in a non contact surgical lens....
... Affinity pacemaker family offers ... truly automatic devices. Featuring ... of advanced technologies ever ... pacemaker incorporates the exclusive ...
... family features St. Jude Medical's ... lead is available in both ... silicone (IsoFlex S lead) models, ... and multiple lead lengths, providing ...
Medicine Products: